PDT Partners LLC Acquires 158,900 Shares of AMNEAL PHARMACEUTICALS, INC. $AMRX

Key Points

• PDT Partners LLC significantly increased its stake in Amneal Pharmaceuticals by 200.7%, acquiring an additional 158,900 shares in the 1st quarter, bringing its total ownership to 238,069 shares valued at nearly $2 million.
• Multiple institutional investors, including Vanguard Group and Invesco, have also raised their positions in Amneal Pharmaceuticals, which is currently 31.82% owned by institutional investors.
• Amneal Pharmaceuticals reported $0.23 earnings per share for the last quarter, exceeding estimates, and has set a guidance for FY 2025 of 0.700-0.750 EPS.

PDT Partners LLC boosted its position in AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX - Free Report) by 200.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 238,069 shares of the company's stock after purchasing an additional 158,900 shares during the period. PDT Partners LLC owned approximately 0.08% of AMNEAL PHARMACEUTICALS worth $1,995,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in the company. GAMMA Investing LLC raised its stake in shares of AMNEAL PHARMACEUTICALS by 5,975.0% during the first quarter. GAMMA Investing LLC now owns 3,159 shares of the company's stock valued at $26,000 after acquiring an additional 3,107 shares in the last quarter. Headlands Technologies LLC acquired a new position in shares of AMNEAL PHARMACEUTICALS in the first quarter worth about $31,000. Amalgamated Bank raised its position in shares of AMNEAL PHARMACEUTICALS by 33.0% during the 1st quarter. Amalgamated Bank now owns 5,511 shares of the company's stock worth $46,000 after purchasing an additional 1,367 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of AMNEAL PHARMACEUTICALS during the 4th quarter worth about $52,000. Finally, Brevan Howard Capital Management LP purchased a new stake in AMNEAL PHARMACEUTICALS during the 4th quarter valued at about $107,000. Institutional investors own 31.82% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on AMRX. Wall Street Zen cut shares of AMNEAL PHARMACEUTICALS from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, May 13th. The Goldman Sachs Group assumed coverage on shares of AMNEAL PHARMACEUTICALS in a report on Friday, June 6th. They set a "buy" rating and a $12.00 target price on the stock. Five equities research analysts have rated the stock with a Buy rating, According to MarketBeat, AMNEAL PHARMACEUTICALS currently has a consensus rating of "Buy" and a consensus target price of $11.60.

Insider Activity

In related news, EVP Nikita Shah sold 6,340 shares of the stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $9.50, for a total value of $60,230.00. Following the sale, the executive vice president owned 146,403 shares of the company's stock, valued at $1,390,828.50. This trade represents a 4.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jason B. Daly sold 22,000 shares of the firm's stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $9.05, for a total transaction of $199,100.00. Following the completion of the transaction, the executive vice president owned 10,606 shares of the company's stock, valued at approximately $95,984.30. The trade was a 67.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 609,206 shares of company stock worth $5,700,625 in the last 90 days. 17.45% of the stock is currently owned by insiders.

AMNEAL PHARMACEUTICALS Trading Up 0.7%

Shares of NASDAQ:AMRX traded up $0.07 during midday trading on Monday, hitting $9.69. The stock had a trading volume of 385,997 shares, compared to its average volume of 1,664,851. The company has a market capitalization of $3.04 billion, a PE ratio of 969.47 and a beta of 1.19. AMNEAL PHARMACEUTICALS, INC. has a 1 year low of $6.68 and a 1 year high of $9.80. The stock has a 50 day moving average price of $8.67 and a two-hundred day moving average price of $8.13.

AMNEAL PHARMACEUTICALS (NASDAQ:AMRX - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $0.23 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.17 by $0.06. AMNEAL PHARMACEUTICALS had a net margin of 0.12% and a negative return on equity of 189.49%. AMNEAL PHARMACEUTICALS has set its FY 2025 guidance at 0.700-0.750 EPS. As a group, equities analysts expect that AMNEAL PHARMACEUTICALS, INC. will post 0.53 EPS for the current year.

AMNEAL PHARMACEUTICALS Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.